CA2985511A1 - Combinaison d'analogues ou de derives de dianhydrogalactitol avec des agents anticancereux contenant du platine pour traiter le cancer - Google Patents

Combinaison d'analogues ou de derives de dianhydrogalactitol avec des agents anticancereux contenant du platine pour traiter le cancer

Info

Publication number
CA2985511A1
CA2985511A1 CA2985511A CA2985511A CA2985511A1 CA 2985511 A1 CA2985511 A1 CA 2985511A1 CA 2985511 A CA2985511 A CA 2985511A CA 2985511 A CA2985511 A CA 2985511A CA 2985511 A1 CA2985511 A1 CA 2985511A1
Authority
CA
Canada
Prior art keywords
dianhydrogalactitol
alkyl
group
aryl
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2985511A
Other languages
English (en)
Inventor
Jeffrey A. BACHA
Dennis M. Brown
Anne STEINO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kintara Therapeutics Inc
Original Assignee
DelMar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/710,240 external-priority patent/US11541027B2/en
Application filed by DelMar Pharmaceuticals Inc filed Critical DelMar Pharmaceuticals Inc
Publication of CA2985511A1 publication Critical patent/CA2985511A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'utilisation de dianhydrogalactitol fournit une nouvelle modalité thérapeutique pour le traitement du carcinome pulmonaire non à petites cellules et du cancer de l'ovaire, ainsi que d'autres types de tumeurs malignes, y compris les métastases cérébrales d'un cancer pulmonaire non à petites cellules. Le dianhydrogalactitol agit en tant qu'agent alkylant sur l'ADN, ce qui donne lieu à une méthylation N7. Le dianhydrogalactitol se révèle efficace pour inhiber le développement de cellules souches cancéreuses et est actif contre les tumeurs réfractaires au témozolomide, au cisplatine et aux inhibiteurs de la tyrosine kinase. Ce médicament agit indépendamment du mécanisme de réparation par la MGMT. Le dianhydrogalactitol peut être utilisé conjointement avec d'autres agents anti-néoplasiques et peut présenter des effets cumulatifs ou super-cumulatifs.
CA2985511A 2015-05-12 2016-05-12 Combinaison d'analogues ou de derives de dianhydrogalactitol avec des agents anticancereux contenant du platine pour traiter le cancer Abandoned CA2985511A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/710,240 2015-05-12
US14/710,240 US11541027B2 (en) 2014-04-04 2015-05-12 Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases
PCT/US2016/032120 WO2016183331A1 (fr) 2014-04-04 2016-05-12 Combinaison d'analogues ou de dérivés de dianhydrogalactitol avec des agents anticancéreux contenant du platine pour traiter le cancer

Publications (1)

Publication Number Publication Date
CA2985511A1 true CA2985511A1 (fr) 2016-11-17

Family

ID=60421889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2985511A Abandoned CA2985511A1 (fr) 2015-05-12 2016-05-12 Combinaison d'analogues ou de derives de dianhydrogalactitol avec des agents anticancereux contenant du platine pour traiter le cancer

Country Status (1)

Country Link
CA (1) CA2985511A1 (fr)

Similar Documents

Publication Publication Date Title
US11541027B2 (en) Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases
US9687466B2 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme
CA2914025C (fr) Utilisation de dianhydrogalacticol et d'analogues et de derives de celui-ci pour traiter un gliome malin recurrent ou une tumeur cerebrale secondaire progressive
AU2015346598B2 (en) Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme
US20160067241A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US20190091195A1 (en) Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
CA2985511A1 (fr) Combinaison d'analogues ou de derives de dianhydrogalactitol avec des agents anticancereux contenant du platine pour traiter le cancer
CN108024987A (zh) 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301